OPR - Delayed Quote • USD NTRA Oct 2024 97.500 call (NTRA241018C00097500) Follow 13.58 0.00 (0.00%) At close: April 8 at 10:24 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NTRA241018C00097500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NTRA Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc 10 Cathie Wood Stocks Insiders are Selling Natera (NTRA) Rose on Momentum in the Oncology Market Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA) Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation 11 Best Biotech ETFs To Buy Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
